Verve Therapeutics Inc.

06/28/2024 | Press release | Distributed by Public on 06/28/2024 05:30

Initial Statement of Beneficial Ownership - Form 3

Ownership Submission
FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104Expires:January 31, 2005Estimated average burden hours per response...0.5
1. Name and Address of Reporting Person *
Politi Jason
2. Date of Event Requiring Statement (Month/Day/Year)
2024-06-26 		3. Issuer Name and Ticker or Trading Symbol
Verve Therapeutics, Inc. [VERV]
(Last) (First) (Middle)
C/O VERVE THERAPEUTICS, INC. , 201 BROOKLINE AVENUE, SUITE 601
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
Chief Technical Ops. Off. /
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)
BOSTON MA 02215
6. Individual or Join/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security 2. Amount of Securities Beneficially Owned 3. Ownership Form: Direct (D) or Indirect (I) 4. Nature of Indirect Beneficial Ownership
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security 2. Date Exercisable and Expiration Date 3. Title and Amount of Securities Underlying Derivative Security 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) 6. Nature of Indirect Beneficial Ownership
Date Exercisable Expriation Date Title Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Politi Jason
C/O VERVE THERAPEUTICS, INC.
201 BROOKLINE AVENUE, SUITE 601
BOSTON, MA02215

Chief Technical Ops. Off.

Signatures

/s/ Andrew Ashe, as Attorney-in-Fact for Jason Politi 2024-06-28
**Signature of Reporting Person Date

Explanation of Responses:

(*) If the form is filed by more than one reporting person, see Instruction 5(b)(v).
(**) Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The option was granted on February 19, 2021. 25% of the shares underlying the option vested on February 25, 2022, and the remainder are scheduled to vest in equal monthly installments thereafter until February 25, 2025.
(2) The option was granted on February 11, 2022. 25% of the shares underlying the option vested on February 11, 2023, and the remainder are scheduled to vest in equal monthly installments thereafter until February 11, 2026.
(3) The option was granted on February 14, 2023. 25% of the shares underlying the option vested on February 14, 2024, and the remainder are scheduled to vest in equal monthly installments thereafter until February 14, 2027.
(4) On February 14, 2023, the reporting person was granted 13,260 restricted stock units, vesting in four equal annual installments that began on April 1, 2024 and the remaining three installments vesting on April 1, 2025, April 1, 2026 and April 1, 2027.
(5) The option was granted on October 16, 2023. 25% of the shares underlying the option will vest on October 16, 2024, and the remainder are scheduled to vest in equal monthly installments thereafter until October 16, 2027.
(6) The option was granted on February 14, 2024. 25% of the shares underlying the option will vest on February 14, 2025, and the remainder are scheduled to vest in equal monthly installments thereafter until February 14, 2028.
(7) On February 14, 2024, the reporting person was granted 22,000 restricted stock units, vesting in four equal annual installments beginning on April 1, 2025 and the remaining three installments vesting on April 1, 2026, April 1, 2027 and April 1, 2028.
(8) Each restricted stock unit represents a contingent right to receive one share of common stock.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.